INTERVIEW: BD On China-Appropriate Growth Strategy
This article was originally published in PharmAsia News
Becton Dickinson has been growing north of 20% several years in a row in China, which has now overtaken Japan to become the U.S. firm’s second largest market. Local needs-based product customization and innovation, and commercial partnerships with national players win the day, says Becton Dickinson China general manager James Deng in an exclusive interview.
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
Increasingly looking to China to commercialize their latest therapies, multinationals may be leaping into unknown waters to navigate an intellectual property judiciary and administrative maze, in a country where some copy drugs have been approved before patent expiry. With a government trying to balance innovation and access, two recent rulings involving AstraZeneca shed rare light onto China’s protections for innovation, with advisors pointing to challenges and success factors.
SinoVac’s rapid antibody response, CanSino’s easier logistics requirements - plus cost advantages - make Chinese developers optimistic about supplying the world with COVID vaccines.